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Type I IFNs are key cytokines mediating innate antiviral immunity.
cGMP-AMP synthase, ritinoic acid-inducible protein 1 (RIG-I)–like re-
ceptors, and Toll-like receptors recognize microbial double-stranded
(ds)DNA, dsRNA, and LPS to induce the expression of type I IFNs.
These signaling pathways converge at the recruitment and activa-
tion of the transcription factor IRF-3 (IFN regulatory factor 3). The
adaptor proteins STING (stimulator of IFN genes), MAVS (mitochon-
drial antiviral signaling), and TRIF (TIR domain-containing adaptor
inducing IFN-β) mediate the recruitment of IRF-3 through a con-
served pLxIS motif. Here we show that the pLxIS motif of phosphor-
ylated STING, MAVS, and TRIF binds to IRF-3 in a similar manner,
whereas residues upstream of the motif confer specificity. The struc-
ture of the IRF-3 phosphomimetic mutant S386/396E bound to the
cAMP response element binding protein (CREB)-binding protein re-
veals that the pLxIS motif also mediates IRF-3 dimerization and ac-
tivation. Moreover, rotavirus NSP1 (nonstructural protein 1) employs
a pLxIS motif to target IRF-3 for degradation, but phosphorylation of
NSP1 is not required for its activity. These results suggest a concerted
mechanism for the recruitment and activation of IRF-3 that can be
subverted by viral proteins to evade innate immune responses.
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The innate immune system of metazoans detects moleculesfrom viral or bacterial pathogens using pattern recognition
receptors to initiate antimicrobial responses (1–4). Type I IFNs,
such as IFN-α and -β, are a major family of cytokines mediating
antiviral immunity (5, 6). A number of innate sensing pathways
stimulate the induction of type I IFNs (1, 3, 7, 8). For example,
microbial dsDNA in the cytosol binds to and activates the en-
zyme cGAS (cGMP–AMP synthase), which catalyzes the syn-
thesis of a cyclic dinucleotide, cGAMP (cyclic [G(2′,5′)pA(3′,5′)p])
(9–13). As a second messenger, cGAMP binds to the adaptor
protein STING (stimulator of IFN genes) located on the endo-
plasmic reticulum (ER) membrane and directs the activation of
transcription factor IRF-3 (IFN regulatory factor 3) through the
protein kinase TBK1 (TANK-binding kinase 1) (7, 11, 14–16).
Phosphorylated IRF-3 (pIRF-3) dimerizes and translocates to
the nucleus to initiate the transcription of the IFN-β gene (17).
In contrast, viral dsRNA in the cytosol is sensed by the RLRs
[ritinoic acid-inducible protein 1 (RIG-I)–like receptors] to acti-
vate IRF-3 via the adaptor protein MAVS (mitochondrial antiviral
signaling) (3, 18, 19). Moreover, the TLRs (Toll-like receptors)
TLR3 and TLR4, which recognize viral dsRNA in the endosome
and bacterial cell wall component LPS, respectively, also medi-
ate the induction of type I IFNs and inflammatory cytokines (1).
These two TLRs use the adaptor protein TRIF (TIR domain-
containing adaptor inducing IFN-β) to mediate the recruitment
and activation of IRF-3 (20–22). Strikingly, the signaling path-
ways of these three families of innate immune sensors converge
at the activation of TBK1 and IRF-3. Mechanistically, the adaptor
proteins STING, MAVS, and TRIF contain a conserved motif,
pLxIS (in which p represents the hydrophilic residue, x represents
any residue, and S represents the phosphorylation site), that is
phosphorylated by TBK1 or IKKe and mediates the recruitment
of IRF-3 to the signaling complexes (23). The induced proximity
between TBK1 and IRF-3 results in IRF-3 phosphorylation and
activation (23). Moreover, IRF-3 itself also contains a pLxIS motif
that is crucial for phosphorylation-induced dimerization and ac-
tivation of IRF-3 (23). Mutations of the phosphorylation site
serine in the pLxIS motif of STING, MAVS, and TRIF abolish
the induction of type I IFNs in their respective signaling path-
ways (23). However, the exact molecular mechanisms of IRF-3
recruitment and activation remain unknown. To elucidate the
structural bases of IRF-3 recruitment by phosphorylated STING
(pSTING), MAVS (pMAVS), and TRIF (pTRIF), we expressed
peptides containing the pLxIS motif from the three adaptor pro-
teins, phosphorylated them in vitro with TBK1, and determined
the crystal structures of their complexes with the IRF-3 C-terminal
domain (CTD) (hereafter referred to as “IRF-3”). To investigate
how phosphorylation activates IRF-3, we determined the structure
of a phosphomimetic mutant S386/396E of IRF-3 bound to a
fragment of cAMP response element binding protein (CREB)-
binding protein (CBP). These structures provide critical in-
sight into the mechanisms of IRF-3 recruitment and activation
in innate immunity.
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Rotavirus is the most common cause of severe diarrhea among
infants and young children. A BLAST homology search revealed
that rotavirus nonstructural protein 1 (NSP1), a RING family E3
ubiquitin ligase, also contains a pLxIS motif within its C-terminal
17 residues. Because the pLxIS motif plays a critical role in medi-
ating the recruitment of IRF-3 in the cGAS-, RLR-, and TLR-
signaling pathways, this motif is likely used by rotavirus to evade
innate immune surveillance. Previous studies showed that NSP1
mediates the ubiquitination and degradation of IRF-3 to suppress
type I IFN induction and that its C-terminal 17 residues are es-
sential for IRF-3 targeting (24, 25). The CTD of IRF-3 is necessary
and sufficient for NSP1-mediated degradation of IRF-3 (26).
However, the exact mechanism by which NSP1 targets IRF-3 is still
not established. In this study, we observed that NSP1 mediates
the degradation of IRF-3 without phosphorylation of its pLxIS
motif. To elucidate the structural basis of IRF-3 targeting by
NSP1, we determined the structures of phosphorylated and
unphosphorylated NSP1 C-terminal peptide bound to IRF-3. These
studies reveal the molecular mechanism by which rotavirus evades
the innate immune surveillance by targeting IRF-3 for degradation.
Results
The Structural Basis of IRF-3 Recruitment by pSTING. To determine
how the phosphorylated STING mediates the recruitment of
IRF-3, we expressed small ubiquitin-related modifier (SUMO)
fusions of the human STING CTD (residues 155–379) and
C-terminal tail (CTT) (residues 342–379) and phosphorylated
them in vitro with TBK1. Surface plasmon resonance (SPR)
binding studies show that IRF-3 binds only to the pSTING
CTD or CTT (Fig. S1 A and C). The affinity of the pSTING
CTD for IRF-3 (Kd ∼48 μM) (Fig. S1B) is comparable to that of
the pSTING CTT (Kd ∼43 μM) (Fig. S1D). These results show
that STING binds to IRF-3 via its C-terminal pLxIS motif
upon phosphorylation.
To elucidate the structural basis of IRF-3 recruitment by
STING, we determined the structure of the pSTING CTT (re-
ferred to as “pSTING” hereafter) bound to IRF-3 (Fig. 1 A and
B and Table S1). The binding site for pSTING is located op-
posite the N and C termini of IRF-3 on a flat surface formed by
helix α2, the loop between strands β6 and β7, and the loop be-
tween strands β10 and β11 (Fig. 1B). pSTING adopts an ex-
tended random coil structure spanning two patches of positively
charged residues and a large hydrophobic groove between them
(Fig. S2 A and B). Compared with the ligand-free IRF-3 struc-
ture (27), restructuring loop5 between strands β10 and 11 ex-
poses the binding surface for the pLxIS motif, allowing IRF-3 to
interact with pSTING (Fig. S2C). The pLxIS motif interacts with
IRF-3 through electrostatic interactions, hydrogen bonds, and
hydrophobic interactions. A cluster of positively charged residues,
Arg285, His288, His290, and Lys313, interacts with pSer366 of
pSTING through electrostatic interactions (Fig. 1B and Fig. S2B).
Residues pSer366, Ile365, and Leu363 form three backbone hy-
drogen bonds with IRF-3. The side chains of Ile365, Leu363, and
Pro361 reach into the long hydrophobic groove of IRF-3 (Fig. S2 A
and B). The SPR binding study shows that the S366A mutation
abolishes IRF-3 binding by pSTING (Table S2), indicating that
phosphorylation of Ser366 is critical for IRF-3 recruitment. The
R285S and K313S mutations of IRF-3 also disrupt interactions
Fig. 1. The structural basis of IRF-3 recruitment by pSTING. (A) Difference map of pSTING bound to IRF-3 contoured at 2.5σ. The σA-weighted Fo-Fc map was
calculated with pSTING omitted from the model. pSTING is shown by the purple ball-and-stick model. The background is a surface representation of IRF-3.
Residues of the pLxIS motif are indicated by asterisks. (B) Close-up view of the pSTING/IRF-3 complex. IRF-3 is shown by cyan ribbons. The two positively
charged clusters of IRF-3 are shown by gray ball-and-stick models. (C) IFN-β reporter assays showing that mutations of potential phosphorylation site residues
affect STING-mediated signaling in HEK293T cells. The data (mean ± SEM) are representative of three independent assays. *P < 0.05, ***P < 0.001, NS (P >
0.05) values were calculated based on comparisons of signals between cells transfected with STING mutants and cells transfected with wild-type STING.
(D) IFN-β reporter assays showing that mutations of key residues of STING involved in IRF-3 binding affect STING-mediated signaling. The data (mean ± SEM)
are representative of three independent assays. *P < 0.05, ***P < 0.001, NS (P > 0.05) values were calculated based on comparisons of signals in cells
transfected with STING mutants and in cells transfected with wild-type STING.
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between pSTING and IRF-3 (Table S2), demonstrating that
Arg285 and Lys313 are critical for pSer366 recognition.
To identify the phosphorylation site of STING that is essential
for IRF-3 recruitment, we mutated each of the four potential
phosphorylated residues (Fig. S1E) to alanine and conducted
IFN-β luciferase reporter assays in HEK293T cells, which do not
express STING (28). As shown in Fig. 1C, the S366A mutation
abolishes IFN-β reporter activation, consistent with previous
studies (23). In addition, the S358A mutation partially impairs
IFN-β reporter activation (Fig. 1C). However, the T376A and
S379A mutations do not affect IFN-β reporter activation (Fig.
1C). These results demonstrate that phosphorylation of Ser366 is
crucial for IRF-3 recruitment. Next, we tested how other residues
within and upstream of the pLxIS motif contribute to STING-
mediated signaling. The L363A and I365A mutations individually
or in combination strongly abolish IFN-β reporter activation (Fig.
1D). In contrast, the E362A and L364A mutations have only minor
effects on STING-mediated signaling (Fig. 1D). The P361A muta-
tion upstream of the pLxIS motif also dramatically reduces IFN-β
reporter activation (Fig. 1D). These results show that the hydro-
phobic interactions between IRF-3 and pSTING residues Pro361,
Leu363, and I365 are also critical for IFN-β induction. Taken to-
gether, these structural and functional studies reveal the structural
basis of IRF-3 recruitment by pSTING.
Mechanisms of IRF-3 Recruitment by pMAVS and pTRIF. In contrast to
dsDNA sensing through the cGAS–STING pathway, the RLRs
sense dsRNA in the cytosol and activate IRF-3 via the adaptor
MAVS (3, 18, 19), and TLR3 and TLR4 use the adaptor TRIF
to recruit IRF-3 (20–22). Phosphorylation of the pLxIS motif of
MAVS or TRIF is required for the recruitment and activation of
Fig. 2. Structures of pMAVS and pTRIF peptides bound to IRF-3. (A) Difference map showing pMAVS bound to IRF-3 contoured at 2.5σ. The σA-weighted Fo-Fc map
was calculated with pMAVS omitted from the model. pMAVS is shown by the orange ball-and-stick model, and IRF-3 is shown by the cyan surface. Residues of the
pLxIS motif are indicated by asterisks. (B) Difference map showing pTRIF bound to IRF-3 contoured at 2.5σ. The σA-weighted Fo-Fc map was calculated with pTRIF
omitted from themodel. pTRIF is shown by the yellow ball-and-stick model, and IRF-3 is shown by the cyan surface. (C) Interactions between pMAVS and IRF-3. pMAVS
is shown by the orange ball-and-stick model. IRF-3 is shown by cyan ribbons. Residues of IRF-3 involved in pMAVS binding are shown by gray ball-and-stick models.
Residues of the pLxIS motif are indicated by asterisks. (D) Superposition of the structures of pMAVS and pSTING bound to IRF-3. pSTING is shown by the yellow ball-
and-stick model. IRF-3 is shown by the surface representation colored according to surface electrostatic potential. The positively charged surface is in blue, and the
negatively charged surface is in red. (E) Interactions between pTRIF and IRF-3. pTRIF is shown by the yellow ribbon with key residues in ball-and-stick models. IRF-3 is
shown by cyan ribbons with residues involved in pTRIF binding shown by gray ball-and-stick models. (F) Structure of pTRIF bound to IRF-3. The ligand-binding surface
of IRF-3 is colored according to surface electrostatic potential as in D. pTRIF is shown by the yellow ball-and-stick model.



























IRF-3 (23). To determine how MAVS and TRIF recruit IRF-3,
we phosphorylated SUMO fusions of peptides containing the
pLxIS motif derived from human MAVS (residues 433–450) and
TRIF (residues 199–219) using TBK1 (Fig. S3 A and F). SPR
binding studies show that pMAVS and pTRIF bind IRF-3 with
affinities of ∼104 and 72 μM, respectively (Fig. S3 B, C, G, and
H). However, unphosphorylated MAVS and TRIF peptides do
not bind IRF-3 (Fig. S3 B and G). A longer fragment of MAVS
containing residues 400–491 binds IRF-3 at a higher affinity of
23 μM when phosphorylated (Fig. S3 D and E). To elucidate the
molecular bases of IRF-3 recruitment by MAVS and TRIF, we
determined the structures of IRF-3 bound to pMAVS and pTRIF,
respectively (Fig. 2 A and B and Table S1). The pLxIS motifs of
pMAVS and pTRIF interact with the same ligand-binding surface
on IRF-3 as pSTING (Fig. 2). However, the interaction of IRF-3
with residues upstream of the pLxIS motif in pMAVS and pTRIF is
different from that in pSTING (Fig. 2 D and E). pMAVS bends
toward helix α2 of IRF-3 at the first residue of the pLxIS motif (Fig.
2 C and D). The side chain of Phe436 sandwiches between the side
chains of Tyr260 and His263 of IRF-3 (Fig. 2C). In contrast, resi-
dues 199–206 of pTRIF form a short α-helix extending toward the
positively charged patch around Arg211 and Lys360 (Fig. 2 E and
F). Ser202 and Ser205 in this helix are also phosphorylated, and
pSer202 is in close proximity to Lys360 (4.9 Å) (Fig. 2E). In addi-
tion, Leu203 upstream of the pLxIS motif reaches into a hydro-
phobic pocket of IRF-3 (Fig. 2 E and F). Mutating the serine
residues in the pLxIS motif to alanine abolishes IRF-3 binding by
both pMAVS and pTRIF (Table S2). Conversely, the R285S and
K313S mutations in IRF-3 also disrupt pMAVS and pTRIF binding
(Table S2). In contrast, the H288S and H290S mutations of IRF-3
or the S202A mutation of TRIF reduce the binding affinities by
only two- to fourfold (Table S2). Taken together, these structural
and functional analyses reveal the molecular bases of IRF-3 re-
cruitment by MAVS and TRIF upon phosphorylation.
The pLxIS Motif of IRF-3 Mediates Its Dimerization and Activation.
IRF-3 contains not only the binding surface for the pLxIS motif to
mediate its recruitment by the adaptors but also a pLxIS motif of
its own to mediate its activation (23). Previous studies showed that
Ser386 and 396 are critical phosphorylation sites for IRF-3 activation
(29, 30). However, the exact mechanism of IRF-3 activation remains
elusive. To determine this mechanism, a double phosphomimetic
mutant of IRF-3, S386/396E, was coexpressed with the IRF-3–
binding domain of CBP and was crystallized for structural analysis
(Table S1). Gel-filtration chromatography and sedimentation ve-
locity analytical ultracentrifugation analyses show that a majority of
the IRF-3 mutant forms a dimer in solution, whereas the unphos-
phorylated IRF-3/CBP complex is mostly monomeric (Fig. 3 A
and B). Consistent with these results, sedimentation equilib-
rium analyses show that unphosphorylated IRF-3 in complex with
CBP is mostly monomeric and dimerizes weakly with an affinity of
∼6 μM (Fig. 3C). Because the C-terminal tail (CTT) of IRF-3 after
Ser398 is truncated, the exposed pLxIS motif likely mediates
the low-affinity binding between two IRF-3/CBP complexes.
Fig. 3. The IRF-3 phosphomimetic mutant S386/396E in complex with CBP dimerizes in solution. (A) Gel-filtration chromatography analyses of IRF-3/CBP
complexes. The black curve is for unphosphorylated IRF-3 bound to CBP. The green chromatogram is for the IRF-3 S386/396E mutant bound to CBP. The red
curve is for the TBK1 pIRF-3/CBP complex. (B) Sedimentation velocity AUC analysis of the samples described in A. The data are consistent with a shift from
primarily monomeric IRF-3 in the unphosphorylated state toward the dimeric state upon phosphorylation. (C–E) Sedimentation equilibrium AUC analyses of
the three IRF-3/CBP complex samples. Protein samples were spun at 18,000, 22,000, and 32,000 rpm in a Beckman An-60 Ti rotor at loading concentrations of
1, 3.5, and 14 μM. Nine datasets for each sample were analyzed globally; for clarity, three representative data curves for each sample are shown. The data are
best described by an equilibrium between 1:1 and 2:2 IRF-3:CBP complexes, with experimental Kd values listed on each plot. In each panel, data from 18,000,
22,000, and 32,000 rpm rotor speeds are shown by squares, circles, and triangles, respectively.
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The S386/396E mutations increase the binding affinity between
IRF-3 molecules to 1.26 μM (Fig. 3D), whereas phosphorylation
of IRF-3 by TBK1 results in a stable dimer with a Kd of 167 nM
(Fig. 3E). To test if the internal pLxIS motif of IRF-3 is responsible
for the high-affinity interaction between two pIRF-3 molecules, we
expressed SUMO fusions of two IRF-3 C-terminal peptides con-
taining residues 382–409 and 382–427 and phosphorylated them
with TBK1. SPR binding studies show that these two peptides bind
IRF-3 with affinities of ∼90 and 68 μM, respectively (Fig. S4), in-
dicating that the intrinsic affinity of IRF-3 for its phosphorylated
tail is comparable to its affinity for phosphorylated adaptor proteins
and that phosphorylation-induced dimerization is critical for the
high stability of the pIRF-3 dimer. The higher affinity between
pIRF-3 molecules compared with the S386/396E mutant is likely
a result of the phosphomimetic mutations being unable to re-
capitulate fully the interactions between two pIRF-3 molecules.
The structure of the IRF-3/CBP complex reveals that the CTT
of IRF-3 containing the pLxIS motif undergoes a dramatic
conformational change from a buried autoinhibitory configuration
(27) to an extended coil that mediates the formation of a domain-
swapped dimer (Fig. 4A and Fig. S5A). The IRF-3 dimer interface
can be subdivided into a smaller central region and tail-mediated
interactions (Fig. 4A). Hydrophobic interactions among Leu299,
Leu300, and Trp358 in loop3 and loop5 form the core of the central
dimer interface, surrounded by Pro357, Thr359, Glu297, Asn302,
Arg213, and Lys360, which forms a salt bridge with Glu297 of the
opposite protomer. The C-terminal tail contributes to more than
two-thirds of the total buried surface area (∼3,800 Å2) at the IRF-3
dimer interface (Fig. 4B and Fig. S5A). Leu387, Val391, Leu393,
and Ile395 reach into a long hydrophobic groove on the surface of
IRF-3 (Fig. 4B). Glu386, the phosphomimetic of pSer386, interacts
with Arg380 upstream of it (Fig. 4A), introducing a bend to the
CTT of IRF-3 so that it can reach into the pLxIS motif-binding
surface of a neighboring IRF-3 molecule. In addition, the electro-
static interaction between Glu388 and Arg211 also contributes to
the dimerization of IRF-3 (Fig. 4A). Glu396, the phosphomimetic
of pSer396, interacts with the positively charged cluster around
Arg285 (Fig. 4 A and C). Of note, the phosphomimetic pLxIS
motif interacts with a neighboring IRF-3 in a manner similar to
that of the phosphorylated pLxIS motif of STING (Fig. 4C).
Because the affinity between the S386/396E mutant of IRF-3
is ∼7.5-fold lower than that of pIRF-3, it is likely that other
phosphorylated residues also contribute to the higher stability of
the pIRF-3 dimer. Indeed, we observed that the phosphorylation
site residue Thr253 is at the IRF-3 dimer interface. It may interact
with Arg380 of a neighboring IRF-3 molecule upon phos-
phorylation. Sequence alignment of IRF-3 and IRF-7, which also
regulates IFN-β induction, reveals that key residues that mediate
IRF-3 dimerization are conserved in IRF-7, suggesting that a
similar mechanism is likely involved in IRF-7 dimerization or IRF-
3/7 heterodimerization.
Comparison of the structures of autoinhibited IRF-3, IRF-3/
adaptor complexes, and the phosphomimetic IRF-3/CBP dimer
reveal the mechanism of IRF-3 activation by the adaptors (Fig. 5
A and B). Binding of pSTING, pTRIF, and pMAVS induces a
major reorganization of loop5 of IRF-3 necessary to create the
binding surface for the pLxIS motif (Figs. 1B and 2 C and E and
Fig. S2C). Binding of the adaptor proteins induces a sharp bend
at Gly349 in loop5 that moves the backbone by as much as 16 Å
(Fig. S2C), forming a solvent-exposed cluster of previously bur-
ied residues, Pro357, Trp358, and Thr359. This reorganization of
loop5 induces a shift in loop3 (Fig. 5 and Fig. S2C), forming a
continuous surface at the central dimer interface. Interestingly,
the central dimer interface is conserved in crystallographic di-
mers observed in the pSTING/IRF-3 and pTRIF/IRF-3 com-
plexes (Fig. S5 B and C), suggesting that this dimer likely
represents a “predimer” configuration that then can be locked
into the domain-swapped active dimer upon phosphorylation of
the IRF-3 tail by TBK1. Comparisons of the structure of the
IRF-3/CBP dimer with the structures of the pSTING/IRF-3 and
pTRIF/IRF-3 complexes reveal that a conformational change in
the loop between β4 and α2 containing residues Gly249 to Asp254
is also required for the formation of the IRF-3/CBP dimer (Fig. S5
D and E). This conformational change moves the loop away from
the IRF-3 dimer interface, avoiding clashes between residues
Fig. 4. Structure of the IRF-3 phosphomimetic mutant S386/396E bound to
CBP. (A) The domain-swapped dimer of the IRF-3 S386/396E mutant bound
to CBP. Key residues mediating IRF-3 dimerization are shown by blue and
pink ball-and-stick models. Residues of the pLxIS motif are indicated by as-
terisks. (B) Structure of the C-terminal tail of IRF-3 (cyan ball-and-stick model)
that mediates IRF-3 dimerization. The IRF-3 dimer with the C-terminal tail
omitted is shown by the surface representation colored according to surface
electrostatic potential. The positively charged surface is in blue, and the
negatively charged surface is in red. (C) Superposition of the pLxIS motifs of
IRF-3 and pSTING. The pLxIS motif of IRF-3 with the S396E mutation is shown
by the blue ball-and-stick model. The pLxIS motif of pSTING is shown by the
yellow ball-and-stick model.



























Leu252 and Val381 and residues Thr253 and Arg380 (Fig. S5E).
Once the highly stable IRF-3 dimer forms, it will be free from
the adaptors and can translocate to the nucleus and initiate
IFN-β transcription. In summary, these structural analyses of the
IRF-3/adaptor and IRF-3/CBP complexes provide critical insights
into the mechanisms of IRF-3 activation in the three innate sensing
pathways.
Interestingly, a causal relationship between the IRF-3 R285Q
mutation and herpes simplex encephalitis has been reported
recently (31). The R285Q mutation of IRF-3 impairs innate
immune responses to herpes simplex virus infection. Consistent
with this finding, the IRF-3 mutation R285D disrupts IFN-β
reporter activation by Newcastle disease virus in IRF-3−/− fi-
broblasts (32). Crystal structures of IRF-3 bound to the adap-
tors and the IRF-3/CBP dimer complex suggest that R285Q or
R285D mutations impair IRF-3 recruitment and activation by
disrupting the electrostatic interactions between the pLxIS motif
and IRF-3. The IRF-3/CBP dimer structure also explains how
dozens of previously reported mutations affect IRF-3 activation
(Fig. S5F) (27, 29, 32–34). Most of these mutations are located at
the tail-mediated IRF-3 dimer interface and play crucial roles in
mediating IRF-3 dimerization (Fig. S5F). Taken together, these
observations unanimously confirm the functional relevance of the
active IRF-3 dimer structure.
Previous structural studies show that there are four IRF-3–
binding sites on the IFN-β enhancer (35, 36). Interestingly, we
observed that the IRF-3/CBP complex forms a tetramer in the
crystallographic asymmetric unit (Fig. S6A). All the IRF-3 N
termini in the tetramer are exposed (Fig. S6A). The avidity of a
similar tetramer of full-length IRF-3 likely facilitates DNA bind-
ing by pIRF-3 and plays a critical role in transcription activation.
Because residues 106–196 of IRF-3 form a long and flexible linker
between its DNA-binding and dimerization domains, it is likely
that no conformational change of the IRF-3 dimers or tetramer as
observed in the structures is needed for efficient DNA binding by
full-length IRF-3. To test this hypothesis, we coexpressed the CBP
fragment with IRF-3 or its S386/396E mutant containing residues
1–398, which include both the DNA-binding and dimerization
domains. Gel-filtration chromatography shows that the pIRF-3
(1–398)/CBP complex forms a tetramer in solution (Fig. S6B),
whereas the phosphomimetic S386/396E mutant of IRF-3(1–398)
bound to CBP is mostly dimeric (Fig. S6C). DNA-binding studies
using a 32-bp dsDNA derived from the IFN-β enhancer, which
contains all four IRF-3–binding sites, show that both the pIRF-3
(1–398)/CBP tetramer and the IRF-3(1–398, S386/396E)/CBP
dimer bind the IFN-β enhancer DNA and form similar large
complexes (Fig. S6 B and C). In contrast, unphosphorylated
full-length IRF-3 is mostly monomeric and does not form a
Fig. 5. Comparison of structures of autoinhibited IRF-3, the pSTING/IRF-3 complex, and the IRF-3/CBP dimer. (A) Comparison of the autoinhibited IRF-3 and
IRF-3/CBP dimer structures. Autoinhibited IRF-3 is shown by yellow ribbons. The key residues at the CTT of IRF-3 are shown by orange ball-and-stick models.
Blue and cyan ribbons show IRF-3 in the IRF-3/CBP dimer structure. CBP bound to the blue IRF-3 is shown by a magenta ribbon. CBP bound to the cyan IRF-3 is
deleted for clarity. (B) Comparison of the pSTING/IRF-3 complex and IRF-3/CBP dimer structures. The pSTING/IRF-3 complex is shown by yellow (pSTING) and
green (IRF-3) ribbons. The key residues of the CTT of IRF-3 are shown by orange ball-and-stick models. The blue and cyan ribbons show IRF-3 in the IRF-3/CBP
dimer structure. CBP bound to the blue IRF-3 is shown by a magenta ribbon. CBP bound to the cyan IRF-3 molecule is deleted for clarity.
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similar high-molecular-weight complex with the same dsDNA
(Fig. S6D). These results indicate the functional relevance of the
IRF-3 dimer and tetramer in IFN-β enhancer DNA binding and
transcription activation.
Rotavirus NSP1 Employs a pLxIS Motif to Target IRF-3 for Degradation.
BLAST homology searches revealed that NSP1 of the simian group
A rotavirus (RVA) strain SA11-4F also contains a pLxIS motif,
which is conserved in NSP1 of rotavirus from other hosts (Fig. S7 A
and B). Previous studies showed that NSP1 targets IRF-3 for
degradation to evade innate immune surveillance (24–26). The
C-terminal 17 residues of NSP1 containing the pLxIS motif are
essential for IRF-3 targeting (24). Consistent with this finding, the
IFN-β luciferase reporter assay shows that full-length NSP1, but not
the ΔC17 truncated form, inhibits IFN-β reporter activation upon
cGAMP stimulation (Fig. 6A). Next, we tested whether phosphor-
ylation of the pLxIS motif is required for the activity of NSP1.
Strikingly, the S489A mutation within the pLxIS motif of NSP1 does
not affect IFN-β reporter suppression (Fig. 6A), indicating that
phosphorylation of NSP1 is not required for IRF-3 targeting. In
contrast, the L486A mutation abolishes the activity of NSP1,
whereas the I488A mutation partially impairs the activity of
NSP1 (Fig. S7C). Consistent with these results, Western blot
analyses show that overexpression of wild-type NSP1 or its S489A
mutant still induces IRF-3 degradation (Fig. 6B). In contrast, either
C-terminal truncation or the L486A and I488A mutations impair
Fig. 6. The pLxIS motif of rotavirus NSP1 targets IRF-3 for degradation and binds to IRF-3 without phosphorylation. (A) Luciferase assays showing that NSP1
suppresses IFN-β reporter activation in HEK293T cells transfected with NSP1 and STING upon stimulation by cGAMP. The S489A mutation does not affect the
activity of NSP1. Mutations L486A/I488A within the pLxIS motif or deletion of the C-terminal 17 residues of NSP1 abolish its ability to suppress IFN-β reporter
activation. The data (mean ± SEM) are representative of three independent assays. **P < 0.01, ***P < 0.001, NS (P > 0.05) values were calculated based on
comparisons of signals in cells transfected with NSP1 mutants and in cells transfected with wild-type NSP1. (B) Western blot showing that wild-type NSP1 and
its S489A mutant mediate IRF-3 degradation in HEK293T cells. Mutations within the pLxIS motif or deletion of the C-terminal residues of NSP1 impair its ability
to target IRF-3 for degradation. (C) Difference map showing pNSP1 bound to IRF-3 contoured at 2.5σ. The σA-weighted Fo-Fc map was calculated with pNSP1
deleted from the model. pNSP1 is shown by the magenta ball-and-stick model, and IRF-3 is shown by the cyan surface. Residues of the pLxIS motif are in-
dicated by asterisks. (D) Difference map showing unphosphorylated NSP1 bound to IRF-3 contoured at 2.0σ. NSP1 is shown by the orange ball-and-stick model.
(E) Superposition of the structures of phosphorylated (magenta) and unphosphorylated (yellow) NSP1 bound to IRF-3 (cyan ribbons). Key residues of IRF-3
involved in NSP1 binding are shown by gray ball-and-stick models. (F) Superposition of structures of pSTING, pMAVS, pTRIF, and pNSP1 bound to IRF-3 and
IRF-3 CTT in the IRF-3/CBP dimer. Key residues involved in IRF-3 binding or IRF-3 dimerization are shown by ball-and-stick models. IRF-3 is shown by the surface
representation colored by surface electrostatic potential. The positively charged surface is in blue, and the negatively charged surface is in red. The five li-
gand-binding sites of IRF-3 are indicated by red circles.



























NSP1-mediated degradation of IRF-3 (Fig. 6B). Consistent with
these cell-based analyses, SPR binding studies show that unphos-
phorylated NSP1 still binds IRF-3 with an affinity of ∼200 μM (Fig.
S8 A and B), whereas phosphorylated NSP1 (pNSP1) binds IRF-3
with a moderate affinity of ∼16 μM (Fig. S8 C–E).
To elucidate the structural basis of IRF-3 targeting by NSP1,
we determined the structures of phosphorylated and unphos-
phorylated NSP1 C-terminal peptides bound to IRF-3 (Fig. 6 C–E
and Table S1). pNSP1 forms an extended coil structure similar to
that of pSTING (Fig. 6C and Fig. S8F). At the N terminus, pNSP1
interacts with IRF-3 through electrostatic interactions between
Glu482 and Arg211 (Fig. 6E). In the middle, Phe484, Leu486, and
Ile488 reach into the hydrophobic groove of IRF-3 (Fig. 6C). Near
the C terminus, pSer489 interacts with the positively charged
cluster around Arg285 (Fig. 6E). Strikingly, unphosphorylated
NSP1 binds IRF-3 in a manner similar to that of pNSP1 (Fig. 6
D and E). Although the electrostatic interactions mediated by
pSer489 are lost, the electrostatic interaction between Glu482 and
Arg211, the hydrophobic interactions, and the hydrogen bonds are
all preserved, suggesting that these interactions mediate the lower-
affinity binding between unphosphorylated NSP1 and IRF-3.
Consistent with this observation, mutation of Leu486 or Ile488
within the pLxIS motif to alanine abolished IRF-3 binding (Ta-
ble S2). The E482A mutation also reduces the binding affinity by
about twofold (Table S2). Taken together, these structural and
functional studies reveal the molecular basis of IRF-3 targeting
by rotavirus NSP1.
Discussion
The cGAS–STING, RLR–MAVS, and TLR–TRIF pathways
in innate immunity converge at the recruitment and activation
of transcription factor IRF-3. The adaptor proteins STING,
MAVS, and TRIF recruit IRF-3 through their phosphorylated
pLxIS motifs. Here, we determined a series of crystal structures
of IRF-3 bound to pSTING, pMAVS, and pTRIF; the activated
IRF-3 dimer bound to CBP; and the complexes of rotavirus
NSP1 bound to IRF-3 to elucidate the molecular mechanisms of
IRF-3 recruitment and activation and viral evasion of the innate
immune response. These comprehensive structural and func-
tional studies reveal that the pLxIS motif not only mediates IRF-3
recruitment but also plays critical roles in IRF-3 activation and in
the targeting of IRF-3 by virus. Although phosphorylation of the
pLxIS motif is needed for IRF-3 recruitment and activation, it is not
required for the targeting of IRF-3 by rotavirus NSP1.
These structural analyses reveal that the pLxIS motifs adopt
similar structures and interact with IRF-3 in similar manners
(Fig. 6F). However, the pLxIS motif alone is not sufficient to
mediate effective binding of IRF-3. Other interactions, such as
the hydrophobic and electrostatic interactions upstream of the
motif, are also critical for IRF-3 binding (Fig. 6F and Table S2).
Based on these structures, we propose a five-site binding model
for proteins containing the pLxIS motif (Fig. 6F). The positively
charged patch around Arg211 interacts with negatively charged
residues or phosphoserine upstream of the pLxIS motif, followed
by binding sites for three hydrophobic residues. At the C ter-
minus, the positively charged cluster around Arg285 recognizes
the phosphoserine of the pLxIS motif (Fig. 6F). All five sites are
used in pNSP1 binding and IRF-3 dimerization, whereas subsets
of these five binding sites are involved in pSTING, pMAVS,
pTRIF, and NSP1 binding. Because the N terminus of the pMAVS
peptide does not interact with site 1 and site 2 of IRF-3, this lack of
interaction likely contributing to the lower binding affinity between
pMAVS and the higher average B-factor of pMAVS peptides in
the crystal structure. It is likely that other proteins containing the
pLxIS motif (23) also interact with IRF-3 in similar manners.
The structural data presented here suggest a model for con-
certed recruitment and activation of IRF-3 by the innate immune
adaptors STING,MAVS, and TRIF. In all three pathways, recognition
of a pathogen-associated molecular pattern (PAMP) leads to the
oligomerization or clustering of the adaptors at membrane surface
(e.g., STING at the ER surface, MAVS at the mitochondrial sur-
face, and TRIF at the inner surface of the plasma or endosome
membranes). Next, the adaptors are phosphorylated on the pLxIS
motif, creating a scaffold with a high local concentration of phos-
phorylated adaptors capable of recruiting IRF-3. Binding of the
phospho-pLxIS motif to IRF-3 induces conformational changes that
begin to reorganize key IRF-3 loops and uncover surfaces involved
in dimerization, whereas colocalization of IRF-3 with TBK1 induces
phosphorylation of the pLxIS motif in the IRF-3 tail. Phosphory-
lation of IRF-3 by TBK1 can occur in vitro but is relatively ineffi-
cient and requires high concentrations (34); colocalization of TBK1
and IRF-3 through recruitment via the adaptors increases local
concentrations of both, thus facilitating the phosphorylation and
dimerization of IRF-3. The scaffold mechanism for IRF-3 activation
would protect effectively against the activation of IRF-3 in the
cytosol by TBK1 until appropriate formation of the innate sig-
naling machinery. Because the pLxIS motif-binding surface of IRF-3
plays critical roles in both IRF-3 recruitment and activation, and
because the adaptors bind to IRF-3 at relatively low affinities, high-
affinity ligands can be designed based on this set of structures to
suppress undesired innate immune responses in autoimmune disor-
ders, such as lupus.
Because the pLxIS motif plays a critical role in mediating the
recruitment and activation of IRF-3 in the cGAS, RLR, and
TLR signaling pathways, rotavirus employs the same motif to
evade innate immune surveillance. Our work presented here
reveals that this motif is used by rotavirus NSP1 to target IRF-3
for degradation. However, it is surprising that phosphorylation of
the pLxIS motif is not essential for NSP1-mediated IRF-3 deg-
radation. Instead, NSP1 binds IRF-3 through hydrophobic resi-
dues within and upstream of the pLxIS motif and acidic residues
flanking the motif, thus avoiding the triggering of innate sig-
naling pathways to activate protein kinases such as TBK1 to
phosphorylate its pLxIS motif. Consistent with this finding, we
observed that NSP1 C-terminal peptide is not a good substrate
for TBK1 and cannot be fully phosphorylated under the same
conditions as STING, MAVS, or TRIF. Extended incubation
with TBK1 at higher concentrations also failed to phosphorylate
the NSP1 peptide fully. Two clusters of negatively charged res-
idues flank the pLxIS motif of NSP1 (Fig. S7B). These residues
are not observed in the sequences of STING, TRIF, and MAVS.
It is likely these residues affect NSP1 phosphorylation by TBK1.
On the other hand, because NSP1 does not have the binding
surface for the pLxIS motif, it is unlikely to be recruited by the
adaptors and phosphorylated by TBK1 at the signaling com-
plexes. However, we cannot rule out the possibility that other
protein kinases may phosphorylate NSP1 and facilitate IRF-3
degradation. It will be interesting to explore if such an elegant
mechanism is unique to rotavirus hijacking of IRF-3. Indeed, a
BLAST search of viral proteomes with the pLxIS motif and the
flanking acidic amino acid clusters revealed that other viral ge-
nomes contain similar sequences (Fig. S8G), suggesting that the
strategy used by rotavirus is likely involved in innate immune
evasion by other viruses.
Materials and Methods
Protein Expression and Purification. The cDNA encoding human STING, human
MAVS, human TRIF, rotavirus NSP1, and human IRF-3 were cloned into a
modified pET28(a) vector with an N-terminal Avi-His6-SUMO tag. For protein
quantification, mutations F378W, M449W, L218W, N495W, Y408W, and E426W
were introduced into human STING (residues 342–379), human MAVS (residues
433–450), human TRIF (residues 199–219), and NSP1 (residues 479–496), IRF-3
(residues 382–409), and IRF-3 (residues 382–427) sequences, respectively. The
cDNA encoding human IRF-3 (residues 189–427, 189–398, 1–398, and full-length)
were cloned into a modified pET28(a) vector with an N-terminal His6-SUMO tag.
The proteins were expressed in Escherichia coli BL21 (DE3) cells induced
with 0.4 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) overnight at
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16 °C and purified using a Ni2+-NTA column (Qiagen). The purified proteins
were cleaved with SUMO protease at 4 °C overnight. The SUMO tag was
removed using a Ni2+-NTA column, and the target proteins or peptides in
the flow through were further purified by gel-filtration chromatography
using a HiLoad 16/60 Superdex 75 column (GE Healthcare) eluted with
20 mM Tris·HCl (pH 7.5) and 150 mM NaCl. Human STING CTD (residues 155–
379) and mouse TBK1 (residues 1–657) were expressed and purified as described
previously (34). SUMO fusion of human CBP (residues 2065–2111) was cloned
into the pET22b(+) vector. IRF-3 (residues 189–398 and 1–398) and CBP were
coexpressed in E. coli BL21 (DE3) cells and purified using a Ni2+-NTA column.
After gel-filtration chromatography on a Superdex 200 column (GE Health-
care), the IRF-3/CBP complex was further purified using a Mono Q 5/50 GL
column (GE Healthcare) eluted with a linear gradient of 0–400 mM NaCl in
50 mM Tris buffer at pH 8.5. Biotin-Avi-His6-SUMO peptides were expressed in
E. coli BL21 (DE3) cells cotransformed with the pET28(a) plasmids coding for
the peptides and the pBirAcm plasmid coding for BirA. Protein expression
was induced with 0.4 mM IPTG in the presence of 5 μg/mL biotin at 16 °C
overnight. The proteins were first purified using a Ni2+-NTA column and
were further purified over a Superdex75 column eluted with 20 mM
Tris·HCl (pH 7.5) and 150 mM NaCl. Mutants of STING, MAVS, TRIF, IRF-3,
and NSP1 were generated using the QuikChange site-directed mutagen-
esis kit (Agilent) or a PCR-based technique with appropriate primers. Se-
quences of all of the plasmids were confirmed by DNA sequencing.
Proteins and Peptides Phosphorylation with TBK1. The purified proteins or
peptides were mixed with GST-mTBK1 in a 10:1 (wt/wt) ratio in 20 mM Hepes
(pH 7.5), 10 mMMgCl2, 100 mM NaCl, 5 mM ATP, 0.1 mMNa3VO4, 5 mMNaF,
5 mM DTT at 27 °C. The concentration of the proteins or peptides was about
1 mg/mL. After 24 h incubation, the phosphorylated proteins or peptides
were concentrated and purified over a Superdex 75 column eluted with
20 mM Tris·HCl buffer with 150 mM NaCl at pH 7.5.
MS. MS analyses of pSTING, pMAVS, pTRIF, pIRF-3, and pNSP1 peptides were
performed using a Shimadzu/Kratos Axima CFR MALDI-TOF mass spec-
trometer. pSTING CTT peptide was analyzed using a Dionex 3000 nRLC
coupled to an Orbitrap Fusion mass spectrometer (Thermo Scientific) to
identify the phosphorylation sites. The sample was injected onto a trap
column for desalting and thenwas eluted onto an analytical column. A 60,000
resolution data MS scan from 650 to 4,000 was obtained, followed by data-
dependent MS2 (second stage of the MS/MS experiment) scans. Both higher-
energy collisional dissociation and electron-transfer/higher-energy collision
dissociation fragmentation were obtained. MS data were analyzed using the
Xcaliber package (Thermo Scientific).
SPR. The binding affinities between IRF-3 and the adaptor proteins or peptides
were determined by SPR using a Biacore X100 SPR instrument (GE Healthcare).
Biotin-labeled SUMO-fusionproteins or peptideswere coupledon the sensor chip
using the Biotin CAPture Kit (GEHealthcare). Dilution series of human IRF-3 (6.25,
12.5, 25, 50, and 100 μM) in 1× HBS-EP+ buffer (GE Healthcare) were injected
over the sensor chip at a flow rate of 30 μL/min. The single-cycle kinetic/affinity
protocol was used in all binding studies. The sensor chip was regenerated
with a buffer containing 6 M guanidine hydrochloride and 0.25 M NaOH. All
measurements were duplicated under the same conditions. The equilibrium
Kd was determined by fitting the data to a steady-state 1:1 binding model
using Biacore X100 Evaluation software version 2.0 (GE Healthcare).
Analytical Ultracentrifugation. All analytical ultracentrifugation (AUC) ex-
periments were performed at 10 °C in a Beckman XL-I analytical ultracen-
trifuge with a Beckman An-60 Ti rotor (item no. 361964) using absorbance
optics. Sedimentation velocity was performed at 48,000 rpm overnight with
8 μM of each sample, and the data were analyzed with the continuous c(s)
distribution model from Sedfit. Partial specific volumes for IRF-3/CBP, S386/396E
IRF-3/CBP, and pIRF-3/CBP were calculated using Sednterp to be 0.7425 (repre-
senting a weight-averaged value for a 1:1 complex of IRF-3 and CBP), and
extinction coefficients were calculated based on amino acid sequence to
be 56,950 M/cm. Sedimentation equilibrium data were collected at 18,000 rpm,
22,000 rpm, and 32,000 rpm using samples loaded at 1, 3.5, and 14 μM concen-
trations. Data for nine curves per sample were analyzed globally usingWinNonlin.
Crystallization, Data Collection, and Structure Determination. Purified IRF-3189–427
was mixed with the peptides in a 1:3 molar ratio with a final concentration of
IRF-3 at ∼7.5 mg/mL. Crystals of IRF-3 in complex with pSTING342–379, F378W,
pMAVS433–450, M449W, and unphosphorylated NSP1479–496 were grown in 0.1 M
Bis-Tris at pH 5.5,∼0.08–0.2MMgCl2, ∼20–25% (wt/vol) PEG 3350. Crystals of IRF-3
in complex with pTRIF199–219, L218W were grown in 0.1M NaAc at pH 4.6 and 2.0M
NaCl. The S386E/S396E mutant of IRF-3 in complex with CBP was crystallized in
0.1 M Hepes buffer at pH 7.5 with 25% (wt/vol) PEG 3350. Crystals of IRF-3 in
complex with pNSP1479–496, N495W were grown in 0.1 M Hepes at pH 7.5 plus 0.8 M
NaH2PO4 and 0.8 M KH2PO4. All proteins were crystallized by hanging-drop
vapor-diffusion method at 4 °C. The crystals were flash-frozen in liquid nitrogen
in the reservoir solution containing either 25% (vol/vol) glycerol or 20% (vol/vol)
ethylene glycol. Diffraction data were collected at the Advanced Light Source
beamlines 5.0.1 using a Quantum 315R CCD detector or a Rigaku R-AXIS IV++
image plate detector at home. The diffraction data for the pSTING/IRF-3, pTRIF/
IRF-3, pNSP1/IRF-3, and NSP1/IRF-3 complexes were processed with the HKL2000
package (37). The diffraction data for the pMAVS/IRF-3 and IRF-3/CBP complexes
were indexed and integrated with iMosflm and merged with Aimless in the
CCP4 package (38). The structure of the pSTING/IRF-3 complex was determined
by molecular replacement (MR) using the structural model of IRF-3 CTD [Protein
Data Bank (PDB) ID code 1QWT] as the search model using Phaser in the Phenix
package (27, 39). The pSTING/IRF-3 complex model was rebuilt with Coot (40).
Structures of the pMAVS/IRF-3 and pTRIF/IRF-3 complexes were determined by
MR using the IRF-3 structure in the pSTING/IRF-3 complex as the search model.
The structure of the IRF-3/CBP complex was determined by MR using the struc-
ture of the IRF-3/CBP complex (PDB ID code 1ZOQ) without the C-terminal tail as
the search model (41). The structures of the pNSP1/IRF-3 and NSP1/IRF-3 com-
plexes were solved by MR using IRF-3 in the pTRIF/IRF-3 complex structure as the
search model. All structures were refined with Phenix (39). Details of data quality
and structure refinement are summarized in Table S1. Pairwise structural su-
perposition was carried out using Superpose in the CCP4 package (38). All
structural figures were generated with PyMOL (https://www.pymol.org).
Cell Culture. HEK293T cells (ATCC, CRL-3216) were cultured in DMEM +
GlutaMAX (Gibco) supplemented with 10% FBS (Gibco), penicillin (100 U/mL),
and streptomycin (100 μg/mL) at 37 °C in a humidified atmosphere with 5% CO2.
IFN-β Luciferase Reporter Assays. The pcDNA3.1 STING carrying a C-terminal
Flag tag was a gift from Cheng Kao (Indiana University, Bloomington, IN).
Mutants of STING were generated using the QuikChange site-directed mu-
tagenesis kit (Agilent). Sequences of all mutants were confirmed by DNA
sequencing. HEK293T cells were plated in CoStar White 96-well plates at 4 ×
104 cells per well. When the cells were ∼80% confluent, they were transfected
with a mixture of Lipofectamine 2000 reagent (Invitrogen) and a constant
amount of IFN-β firefly luciferase reporter plasmids (20 ng per transfection),
phRL-TK–Renilla luciferase plasmids (2 ng per transfection) (Promega), and
plasmids of either wild-type or mutant STING (0.2 ng per transfection). Empty
pcDNA3.1 plasmid was used as transfection control. The cells were incubated
for a further 24 h to allow the expression of the genes and then were treated
with 30 μg/mL cGAMP. After 16 h incubation, the cells were analyzed using the
Dual-Glo Luciferase Reporter Assay Kit (Promega). Luminescence was quanti-
fied with the BioTek Synergy HTX Multi-Mode microplate reader. The relative
firefly luciferase activity was normalized by the Renilla luciferase activity. The
relative IFN-β reporter fold of induction represents the ratio normalized to
control plasmid values with the same treatment. The inhibition of IRF-3 acti-
vation by NSP1 and its mutants was evaluated by a luciferase-based inhibition
assay. The indicated amounts of NSP1 variant plasmids were cotransfected
with a constant amount of IFN-β firefly luciferase reporter plasmids (20 ng per
transfection), phRL-TK–Renilla luciferase plasmids (2 ng per transfection), and
wild-type STING (0.2 ng per transfection). After cGAMP stimulation (30 μg/mL),
the luminescence assay and data analysis were performed as described above.
Western Blot. HEK293T cells were washed and suspended in PBS. The cells
were lysed in 200 mM Tris·HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, and 1%
Nonidet P-40 supplemented with one complete EDTA-free protease inhibitor
mixture tablet (Roche) and one PhosSTOP phosphatase inhibitor mixture
tablet (Roche) for each 10 mL of lysis buffer. The proteins were resolved by
SDS/PAGE and transferred to PVDF membrane, which then was incubated
overnight with primary antibodies. The following antibodies were used in the
Western blot analyses: anti–IRF-3 (1:1,000l; sc-9082; Santa Cruz), anti-Flag
M2-Peroxidase (1:2,000; A8592; Sigma), and anti-Actin (1:5,000; HHF35;
Pierce). Except for flag-tagged proteins probing, the membrane was further
incubated with the corresponding HRP-conjugated secondary antibodies.
Proteins of interest were visualized using the Western Lightening Plus ECL
(PerkinElmer) according to the manufacturer’s protocol.
Statistical Analysis. For all figures, statistical analyses were carried out using
Microsoft Excel. All data are presented asmean± SEM. A two-tailed Student’s t
test assuming equal variants was used to compare two groups. In all figures,
the statistical significance between the indicated samples and control is des-
ignated as *P < 0.05, **P < 0.01, ***P < 0.001, or NS (P > 0.05).
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